Impact of tumour burden on chemotherapy-induced nausea and ...
Recommend Documents
Conclusions: Despite prophylaxis with antiemetic drugs, nausea and emesis were significant problems in this population receiving chemotherapy.
Oct 16, 2014 - G 40 ug/kg. IV: intravenous; ASA, American Society of Anesthesiologists; D: dexamethasone; T: tropisetron; O: ondansetron; G: Granisetron.
Burden of disease and factors associated with nausea and vomiting in pregnancy among currently pregnant mothers in Anuradhapura. Thilini C Agampodi ...
diagnosed with olfactory neuroblastoma. In this study only 2 cases were confirmed as neuroblasto- ma whereas 10 patients had in fact other tumours such as ...
Dec 10, 2014 - Lutz Kretschmer & Hans Peter Bertsch & Pawel Bardzik &. Johannes Meller & Simin Hellriegel & Kai-Martin Thoms &. Michael Peter Schön ...
Received: 04 March 2013; Accepted: 23 May 2013 ... Overall, in-hospital death occurred in 121 patients (0.11%) and 4,448 patients (4.2%) had at least one ...
Radiobiology based head & neck cancer protocol (FAMOSO) combining accelerated RT and EGFr inhibitor. D. Alterio1, M. Cremonesi. 1European Institute of ...
was diminished and often non-medication therapies and complementary and ..... Auricular acupressure therapy in treatment of nausea and vomiting in early ... Deadman P, Al-Khafaji M, Baker K. A Manual of Acupuncture. East- land Press ...
er's Bureau, Consulting fee, Grant recipient and Speaker honorarium Gilead Sciences: ... and Speaker honorarium Merck: Consultant, Grant Investigator and ...
May 28, 2013 - ... Horiguchi2, Katsushi Takeshita1, Shurei Sugita1, Shuji Taketomi1, ..... Nakamura K: Mortality and morbidity in dialysis-dependent patients.
May 28, 2013 - Charlson comorbidity index was used to identify and summarize patients' ... After adjustment, mortality following lumbar arthrodesis or cervical.
Received 29 May 2012; accepted 2 August 2012. KEYWORDS ... The net burden caused by alcohol consumption was 1 in 7 deaths in men and. 1 in 13 deaths ...
$63 and the indirect cost $121. Conclusions: Despite prophylaxis with antiemetic drugs, nausea and emesis were significant problems in this population ...
Bernie J. O'Brien,* PhD; James Rusthoven,t MD; Angela Rocchi,: MSc; Jean Latreille,§ MD;. Sheldon Fine,¶ MD; Ted Vandenberg, MD; Francis Laberge,** MD.
Feb 10, 2016 - Ellis C, Simpson AN, Bonilha H, Mauldin PD, Simpson KN. The one-year attributable cost of poststroke aphasia. Stroke J Cereb Circ. 2012; 43: ...
Feb 13, 2014 - The Burden of Communicable Diseases in Europe (BCoDE) project ... A comprehensive assessment of the overall impact of a disease requires ...
that initially motivates patients to seek professional med- ical help [8, 9]. ..... distress than patients with other chronic medical condi- tions, and that lack of ..... PLoS Med. 2006;3:e442. 3. .... 2014;11:451â8. ⢠We accept pre-submission in
We evaluated the antitumour efficacy of CCL19 in a murine model of spontaneous ... CCL19 treatment led to a marked reduction in tumour burden with extensive.
for micrometastases [2] and then for low burden axillary macrometastatic disease [3, 4] identified at sentinel node biopsy (SNB)âin the presence of systemic ...
toms and a median Halabi-predicted survival (HPS) of 21 months. A smaller study (n = 32) of PSA-TRICOM reported an overall survival of 26.6 months, with.
all abscopal lesions were summed. Baseline and post- treatment measurements of abscopal lesions were compared. Abscopal responses were reported as: CR ...
In an effort to ensure more equity in personal income taxation, the Croatian Government adopted a new, amended Personal. Income Tax Act that entered into ...
is funded by ESRC grant ES/F3000537/1 and by the University of Essex. ... Emanuela Sala, ISER, University of Essex, Wivenhoe Park, Colchester, CO4 3SQ, UK ...
Impact of tumour burden on chemotherapy-induced nausea and ...
Impact of tumour burden on chemotherapy-induced nausea and vomiting. TJ Hursti 2, E Avall-Lundqvist3, S B6rjeson4, M Fredrikson2, CJ First4, G Steineck5 ...
Impact of tumour burden on chemotherapy-induced nausea and vomiting TJ Hursti 2, E Avall-Lundqvist3, S B6rjeson4, M Fredrikson2, CJ First4, G Steineck5 and C Peterson6 'Department of Clinical Neuroscience, Karolinska Institute, S-171 76 Stockholm, Sweden; 2Department of Clinical Psychology, Uppsala University, Box 1225, S-751 42 Uppsala, Sweden; Departments of 3Gynaecological Oncology, 4Oncology, 5Cancer Epidemiology and 6Clinical Pharmacology, Karolinska Institute and Karolinska Hospital, Radiumhemmet, S-171 76 Stockholm, Sweden. Summary We investigated how residual tumour burden after cytoreductive surgery was related to the occurrence of acute and delayed nausea and vomiting in 101 ovarian cancer patients receiving their first chemotherapy course. The anti-emetic treatment included ondansetron combined with dexamethasone or placebo. After chemotherapy all patients received ondansetron only for 5 days. Two categories of tumour burden (TB) were formed according to the diameter of the greatest residual tumour ( 2 cm= large TB). Self-reports of nausea and vomiting were obtained for 15 days. Other potential predictor variables were assessed and included in multivariate analyses. Patients with large compared with minimal TB had more delayed emesis, especially on days 2-7. They also had more acute nausea. The aggravating effect associated with large residual TB was more evident in patients >55 years. During the second week after the chemotherapy the occurrence of nausea was higher in patients >55 years than in those
